Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 228.00 220.00 236.00 228.00 228.00 228.00 43,910 07:32:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 74.6 15.2 17.6 13.0 154

Eco Animal Health Share Discussion Threads

Showing 226 to 249 of 1100 messages
Chat Pages: Latest  20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
06/7/2011
08:19
I agree Topvest that the FDA approval is so material to the company that it will need to be announced once known.We should at least receive an update on progress on the 25th unless, of course, it has been granted prior.I am still confident that a takeout in excess of £5 per share will be achieved and note the activity at Axis Shield today.
ltinvestor
04/7/2011
20:21
Yes, sounds good. The FDA approval would need to be announced once it is known rather than waiting for the results though. Patience required, but no doubt it will be granted at some point.... maybe in a few weeks, months or years!
topvest
04/7/2011
09:27
A bit of news at last and a hint that things are going well. May we finally get news of FDA approval on 25th?
audigger
15/6/2011
14:55
In the meantime, the company has to wait to get full value for its IP. FDA should compensate!
audigger
13/6/2011
06:58
The delay just goes to show how difficult it is to obtain FDA approval for a drug which is already approved and being used in many countries globally.It also shows how valuable this drug will be once approved. I look forward to the day!
ltinvestor
27/5/2011
20:45
Have been trawling FDA's website in search of any clues as to pending US approval for aivlosin. One intersting point I noted was that EAH appear to have a lead regulatory person in the USA by the name of Dr Robert Dodemaide (Director, Regulatory Affairs & Compliance at ECO Animal Health). I was able to find some transcripts from some generic discussions involving FDA and insustry in which DR Dodemaide features. I've copied some of this below. Most of the subject matter is irrelelevant to Aivlosin approval in the USA but, as is the way of things with chemical approvals, he is likely to be the key interface between EAH and FDA in terms of securing FDA approval of aivlosin. DR. DODEMAIDE: Good afternoon. My name is Robert Dodemaide. I work for Eco Animal Health, and my office is located in Princeton, New Jersey. Headquarters is in London, UK. Comments on two different subjects. Firstly about what should be the title of the person who could be Steve Sundlof in the EU, and the title suggested was a MUMS Czar. My suggestion is Big MUMA. (Laughter.) DR. CRAIGMILL: You might be earning yourself 10. Keep going. (Laughter.) DR. DODEMAIDE: My second subject is about MUMS and I have sort of entitled it data package transfer from jurisdictions where a use is a major use to a jurisdiction where a use is a minor use. There have been several examples shown during the course of the day. For example, sheep is a major use in the UK; sheep is a minor use in the US. Turkeys is a major use in the US, but a minor use in Europe. So I will just read some comments that I jotted down, and I will give these to the recorder over there when I'm finished if that makes it easy. All regulators want products which are safe and effective, and to insure that we have VICH guidelines, we have Codex procedures, we have JECFA to make various determinations to insure that this happens more or less on a global and a harmonized scope. Products for major uses go through a rigorous review process for quality, safety, and efficacy. We all know that. Major uses in one country may only be a minor use in another, and I gave a couple of examples of that. Turkeys in the US, major, minor in Europe. Sheep in the UK are major, minor in the US. A data package from a major-use country should be accepted in a minor-use country. I think really accepted in fact because this package which has come from a major-use country has gone through a rigorous review process. I am using those two examples of sheep in the UK and turkeys in the US for those products that have an approval where they are a major use. They have gone through a very rigorous process, and I think the package should be able to simply be transferred post-approval in the major-use jurisdiction to the jurisdiction where it is a minor use. I think this system would provide a package of data that is of good quality data that might otherwise not be available in a minor-use jurisdiction. So for example, if we ignored what happened in Europe and wanted a sheep approval, you would have to go through the MUMS procedure here and perhaps generate data which are not complete in the normal sense. Whereas in the UK, there would be a complete data package available for say an anti-parasitic drug for use in sheep. So under this proposal I would say the quality and safety should not be a problem. The manufacturing of this product would already be underway in the country where it is a major use beyond the CGMP, and that probably could be exported to the country where it is a minor-use jurisdiction. Safety should not be a problem because in the major-use jurisdiction it has gone through this rigorous process. There has been an ADI, a safe concentration, safe MRL, et cetera, and really what is acceptable in one jurisdiction where it has a rigorous review process I think should be accepted without too much question where the minor-use is proposed. There might be some problems with it, but I think the quality of the data generated under this sort of a standard would be far superior to that which might be generated under the MUMS proposals that we have been sort of talking about today. I think a sheep anti-parasitic drug efficacy package generated in the UK would be a rigorous package which would cover several species, and it would be a much more complete and thorough package than might be generated in the US under the MUMS procedure. I think my final bullet point here would be the label for a drug approved under this data transfer, data package transfer scheme, could be a new label if it was the first time the product had been approved, or it could be added to a current label. I am not sure if that would raise any legal questions, but perhaps it could read "approved, FDA in parens, MUMS" or something like that, just to show to the consumer that the full safety and efficacy package was not generated in the minor-use jurisdiction. All that data came from overseas. So that is just my thought on a data package transfer from a major-use jurisdiction to a minor-use jurisdiction. DR. CRAIGMILL: Okay. Thank you very much, and you also have the opportunity to participate in the discussion with respect to all the other things. Was there anyone else who wishes a public comment? We have two, so what is our time? I guess we will have to give you each three minutes this time. Roz? Sandy, would you set it for three?
audigger
11/5/2011
14:04
And an share price of >500! That would be nice.
audigger
11/5/2011
07:35
>Audigger.Once FDA approval is received they will be knocking quite loudly on Eco's door.I think that £300m would be achievable.
ltinvestor
11/5/2011
07:27
All quiet on the EAH front. I thought this FT article was intesting in that there are two companies actively seeking acquisitions on the animal health front: Sanofi to expand animal health business //10 May 2011 Sanofi-Aventis plans to cut costs and expand its animal health business through acquisitions as it fully integrates Merial after the collapse of its longstanding joint venture with Merck of the US, The Financial Times writes As of Friday May 6, Sanofi-Aventis shareholders approved a name change. From now on the company is known as Sanofi. Chris Viehbacher, chief executive of the French pharmaceutical group, told the Financial Times there was scope for "synergy" in back office operations, manufacturing, marketing, and research and development. He said the failure of the partnership meant Sanofi-Aventis would seek new takeover targets in animal health and plan to grow, notably in emerging markets where animal health sales contributed a smaller proportion than other divisions in the group. Failure reasons In the first detailed comments by either company on the reasons for the failure, Viehbacher said that the failure to recombine the two companies' animal health divisions was caused by difficulties in clearly defining market share and concentration in a way that permitted international regulatory approvals. The process led to repeated delays and Viehbacher said that one cannot put a business on hold, stressing that both companies would have preferred to maintain the joint venture. The current structure allows Sanofi-Aventis to fully consolidate its animal health operations. Seeking acquisitions He said Merial was likely to seek acquisitions "probably not of significant size" as it expanded, stressing that it generated only a fifth of its sales in emerging markets compared with a third for the group overall. It would also seek closer links to joint development of human and animal treatments.
audigger
06/4/2011
16:46
I have more experience with EPA aprpovals than FDA. EPA now operate a fee-paying system which places an obligation on them to evaluate new applications within a defined timeframe. That said if the agency rules the database incomplete the onus is back on the registrant to address the data gaps and timelines change. I'm not sure if FDA had open questions on Eco's data that needed to be addressed by the company or if the delay was purely down to FDA struggling to meet its work load. If its the latter, you would hope that ECO aren't punished in terms of time to off-patent. I'm working on the premise that approval will be granted this year, but have no insight as to when
audigger
06/4/2011
14:51
Tightly held stock, mm's short and news around the corner.I have no doubt that Aivlosin will receive FDA approval but when I can't be sure, although I suspect sooner rather than later.The fact that the company haven't put a news release out recently indicates to me that they must be very close to achieving approval.
ltinvestor
06/4/2011
14:36
Au. I thought we would have FDA news by now??
joeblogg2
06/4/2011
14:34
Nice to see this gaining some upward momentum again after the drift down. Will be interesting to see if it can get to 280 again even without FDA news. With FDA news it could go 300+ very quickly
audigger
14/3/2011
14:47
Its good to see this kind of proactive update. I was wondering if the big fall this am was due to concerns over the Japanese side of the business. This update is reassuring. However, it doesn't feel appropriate to be too focused on the impact on personal investments given awful events in Japan.
audigger
11/2/2011
15:49
Agreed. Patience required!
topvest
11/2/2011
15:30
Very illiquid stock so when they finally receive FDA approval it will,imho, go up many times todays fall.
ltinvestor
11/2/2011
13:44
News leaking ? However minimal volume. BBB.
pugugly
11/2/2011
09:30
Ouch, that's a bit more than a drift!
audigger
08/2/2011
19:00
I guess its not surprising that this will drift back down after the recent surge whilst awaiting US approval. Sounds like they are on-track for another good set of results. Trying to decide when is a good time to add. Thinking I will wait a few weeks with an expectation it will drift lower. I think the market is also over-due a downward correction so, if that happens, they may become even cheaper. Time will tell!
audigger
04/2/2011
10:20
Thursday, February 03, 2011 ECO Animal Health: growing fast while awaiting US launch The livestock therapeutic specialist is continuing organic growth in China, Latin America and India. In the shorter term, investors will want to look out for news of US regulatory approval for its flagship product Aivlosin this year as well as full-year results that are expected to show a substantial increase in both turnover and profits. Longer term, a trade sale may be on the cards, chairman Peter Lawrence tells Proactive Investors. http://www.proactiveinvestors.co.uk/companies/news/25217/eco-animal-health-growing-fast-while-awaiting-us-launch-25217.html
aim_trader
12/1/2011
22:55
Positively flying!
audigger
12/1/2011
20:26
Absolutely, going vertical!
topvest
11/1/2011
12:39
we are off again
shroder
05/1/2011
15:23
joeblogg2 - The results in August mentioned FDA approval in the "current financial year" . This was a month or so before the "heavy workload " statement regarding the FDA . I suppose this could in theory mean approval not until after March ....
roverite12
Chat Pages: Latest  20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191115 20:25:06